A boxed warning has been added to the label for Liraglutide, effective January 30, 2026. This significant label revision highlights the risk of thyroid C-cell tumors associated with the drug.
Background
Liraglutide is a medication marketed under several brand names, including Xultophy 100/3.6, Saxenda, and Victoza. The FDA has issued a major label revision for Liraglutide, incorporating a boxed warning—the strongest warning the FDA requires—to highlight a significant safety concern. The specific warning states: 'WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether liraglutide causes th'. This warning indicates that while animal studies have shown a clear link between Liraglutide and the development of thyroid C-cell tumors, the risk in humans remains undetermined.
What this means
The implementation of a boxed warning on the Liraglutide label represents a critical update for all stakeholders involved in patient care, including clinicians, researchers, and patient advocates. Effective January 30, 2026, this warning necessitates that healthcare providers carefully weigh the potential for thyroid C-cell tumors, as observed in preclinical studies, against the therapeutic benefits of Liraglutide for individual patients. The FDA's decision to issue this highest-level warning underscores the seriousness of the observed animal data, even as the human risk remains unconfirmed. This revision emphasizes the importance of thorough patient education regarding these potential risks and vigilant monitoring for any signs or symptoms that could indicate thyroid C-cell abnormalities during treatment with Liraglutide. It also suggests a need for ongoing research to clarify the human relevance of these preclinical findings.
Source
The information regarding this label revision for Liraglutide was sourced from the FDA, specifically a document detailing the boxed warning on the drug's label. The effective date of this revision is January 30, 2026. The official record is available on dailymed.nlm.nih.gov.